Baxter Bros Inc. Invests $3.54 Million in Edwards Lifesciences Corporation $EW

Key Points

• Baxter Bros Inc. purchased 39,184 shares of Edwards Lifesciences, valued at approximately $3.54 million. Institutional investors and hedge funds collectively own 79.46% of the company.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in earnings per share versus the $0.74 consensus estimate, while revenue rose 13.6% year over year to $1.74 billion.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $100.27, compared with the stock’s reported price of $91.51.

Baxter Bros Inc. purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 39,184 shares of the medical research company's stock, valued at approximately $3,545,000.

A number of other large investors have also recently added to or reduced their stakes in EW. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter valued at $26,000. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth $25,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $28,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 0.1%

NYSE EW opened at $91.51 on Monday. The firm has a 50 day simple moving average of $88.73 and a 200-day simple moving average of $84.38. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The firm has a market cap of $52.69 billion, a price-to-earnings ratio of 52.59, a PEG ratio of 2.30 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same quarter in the previous year, the business posted $0.67 earnings per share. The business's quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. Evercore reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a "hold" rating in a report on Friday, April 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Mizuho boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Finally, Citigroup boosted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source